NC 6 Plateforme de g enomique des cancers, Centre L eon B erard, Laboratoire de la g en etique constitutionnelle HCL-CLB, Lyon, France BRCA1/2 are cancer predisposition genes involved in hereditary breast and ovarian cancer (HBOC). Mutation carriers display an increased sensitivity to inhibitors of poly(ADP-ribose) polymerase (PARP). Despite a number of small-size hospital-based studies being previously reported, there is not yet, to our knowledge, precise data of BRCA1/2 mutations among Chinese ovarian cancer patients. We performed a multicenter cohort study including 916 unselected consecutive epithelial ovarian cancer (EOC) patients from eastern China to screen for BRCA1/2 mutations using the next-generation sequencing approach. A total of 153 EOC patients were found to carry pathogenic germline mutations in BRCA1/2, accounting for an overall mutation incidence of 16.7% with the predominance in BRCA1 (13.1%) compared with BRCA2 (3.9%). We identified 53 novel pathogenic mutations, among which the c.283_286delCTTG and the c.4573C > T of BRCA1 were both found in two unrelated patients. More importantly, the most common mutation found in this study, c.5470_5477del8 was most likely to be Chinese populationrelated without an apparent founder origin. This hot-spot mutation was presumably associated with an increased risk of ovarian cancer. Taken together, germline BRCA1/2 mutations were common in Chinese EOC patients with distinct mutational spectrum compared to Western populations. Our study contributes to the current understanding of BRCA1/2 mutation prevalence worldwide. We recommend BRCA1/2 genetic testing to all Chinese women diagnosed with EOC to identify HBOC families, to provide genetic counseling and clinical management for at-risk relatives. Mutation carriers may also benefit from PARP-targeted therapies.
substantial inter-individual heterogeneity of genetic predisposition associated with EOC risk, and approximately 20-25% of EOC can be ascribed to germline mutations in BRCA1 or BRCA2. 4 In women, BRCA1 and BRCA2 mutations result in a lifetime risk of 39-44% and 11-18% of developing ovarian cancer, respectively. 5, 6 The importance of BRCA1/2 mutation screening in ovarian cancer patients has been further underscored since mutation carriers demonstrated an increased sensitivity to inhibitors of poly (ADP-ribose) polymerase (PARP). 7, 8 In fact, PARP inhibitors have recently been approved for the treatment of advanced ovarian cancer patients carrying either germline or somatic mutations in BRCA1 or/and BRCA2 genes. 9 The reported prevalence of BRCA1/2 mutations in patients with ovarian cancer varies in different studies among distinct ethnic populations. A recent meta-analysis based on 14 studies from eight countries has shown that, although the overall incidence of germline mutation was 18.0% for BRCA1 and 6.9% for BRCA2, the incidence ranged considerably in different populations: 3.4-47% for BRCA1 and 1-12% for BRCA2. 10 In an Australian population, the incidence of BRCA1/2 mutations was reported to be 14.1% among 1,001 Caucasian women diagnosed with invasive epithelial ovarian, peritoneal, or fallopian tube cancers. 11 Another recent population-based survey combining a UK cohort and a hospital-based Mayo clinic study from USA found that 3.8% and 4.2% of EOC patients carrying BRCA1 and BRCA2 mutations, respectively. 12 The variation in mutational incidence was very likely due to certain founder mutations identified in several populations such as c.185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 in Ashkenazi Jewish population. 13 However, relatively few studies have been reported for Asian population and most available results are based on small-size cohorts. One study from South Korea 14 described that among 37 EOC patients, only one pathogenic mutation was found in the BRCA1 gene. A recent study in 95 Japanese EOC patients reported the frequency of 5.3% cases with germline mutations in BRCA1 and 7.4% in BRCA2. 15 Regarding Chinese populations, to our knowledge, the only cohort study was reported by Khoo et al. 16 from Hong Kong. In a series of 60 ovarian cancer patients analyzed for the whole coding region of BRCA1 but only the exon 11 of BRCA2, mutations were detected in, respectively, 11.3% and 2.1% of patients, among which c.1081delG in BRCA1 seemed to be a founder mutation from southern Chinese. In addition, two recurrent mutations were identified including c.2371-2372delTG in BRCA1 and c.3337C > T in BRCA2.
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In an attempt to gain a more complete insight into the prevalence of BRCA1/2 mutations in Chinese EOC patients and their associations with clinical and genetic characteristics, we performed a cohort study with a large series of unselected consecutive EOC patients for BRCA1/2 mutation screening using the next-generation sequencing (NGS) approach.
Material and Methods

Study subjects
This study was performed on a total of 916 EOC patients based on two series of samples collected for previous studies between 2010 and 2016, independently of PARP inhibitors' clinical trials. A consecutive series of 133 EOC patients was from Zhongshan Hospital, Fudan University (FDUZH). Another 783 samples were collected by Shanghai Ovarian Cancer Study as described previously in the Chinese EOC genome-wide association study, mainly from Fudan University Cancer Hospital (FDUCH). 18 Clinical and pathological data of all cases were provided in Supporting Information Table S1 . All 916 cases were unrelated Chinese Han women, mainly from eastern area (Fig. 1) . Tumor histology was confirmed by two independent examinations by gynecologic pathologists as routine diagnosis. The detailed clinical and pathological information was extracted from the institutional patients' database, including age at diagnosis, tumor histopathology, grade, FIGO stage (International Federation of Gynecology and Obstetrics, 2013), personal and family history of cancer when available. Hereditary breast and ovarian cancer (HBOC) syndromerelated tumors were defined as breast, ovarian, pancreatic cancers in women and cancers of breast and prostate in men. Samples with incomplete or undetermined histological diagnosis were described as "unknown". Because of the small-size nuclear family by Chinese family planning, only for five EOC patients with a family history of ovarian cancer, blood sample from their first-degree relatives were also collected (e.g., Y0101, EOC0276, Y0201, Y0701 and 224). This research project was approved by the Institutional Review Board of FDUZH and FDUCH. Blood samples from each of the subjects were collected after they signed a written informed consent.
DNA extraction
Genomic DNA was extracted from each blood sample using the Qiagen Blood DNA Kit (Qiagen, Valencia, CA) according What's new? Mutations in BRCA1 and BRCA2 are well-characterized predisposing factors in ovarian cancer. Recent studies suggest, however, that their incidence varies considerably between ethnic populations. In the present evaluation of BRCA1/2 mutational spectrum in Chinese women with epithelial ovarian cancer, pathogenic mutations were found to occur in more than 16% of cases. Next-generation sequencing further led to the identification of novel pathogenic mutations and Chinese ethnic-related hotspot variations. Such novel insights into population-based BRCA1/2 mutational prevalence and characteristics can potentially aid genetic counseling and the selection of patients who stand to benefit from poly (ADP-ribose) polymerase-targeted therapy.
to the manufacturer's instructions. DNA purity and concentration were detected by a UV spectrophotometer (Nano Drop Technologies, Wilmington, DE).
Mutation screening using NGS approach
The BRCA1/2 panel (Morgen, China) was used which covers the entire coding sequences of BRCA1 and BRCA2 including 10-50 bases of adjacent intronic sequence of each exon. According to the manufacturer's instructions, 120 amplicons were divided into two separate multiplex PCR amplification reactions (A/B Pools). 50 ng of sample DNA was added to each of the two reactions. PCR and the purification of PCR products were performed under the conditions according to the manufacturer's instruction. After adding barcode and adaptors for Miseq (Illumina) using PCR reagents supplied by Illumina, the quality of PCR products were checked with Agilent 2100 Bioanalyzer (Agilent Technologies). The sequencing process was carried out according to Illumina's protocols (Illumina, San Diego, CA) using MiSeq V.2 300 cycle reagent cartridge corresponding to 2 3 150 bp paired end configuration. The average depth of each run was over 2003. After the sequencing, the Illumina Genome Analyzer II was used to generate the sequencing reads, alignment and variant calling. A variant was called when the minimum depth of coverage is 203, with allele directional balance of 15%, and mutation threshold of 10%.
Sequence variations were described according to the nomenclature (www.hgvs.org) with the use of reference sequence of NM_007294.3 (hg38) for BRCA1 and NM_000059 (hg38) for BRCA2. The variants were classified based on widely accepted 5-class classification. 19 Truncating mutations and splicing mutations were clearly defined as Class 5 or pathogenic. 3 One is endometrioid/transitional cell, one is endometrioid/serous, one is endometrioid/clear cell and the fourth one is clear cell/mucinous. 4 HBOC, hereditary breast and ovarian cancer; HBOC-related tumors were defined as cancers of breast, ovary, pancreatic cancers in women and cancers of breast and prostate in male relatives.
Sanger sequencing
Sanger DNA sequencing was used to confirm all reported variants (Classes 3-5) starting from the original sample using the specific gene primers.
Statistical analysis
We performed Student's t test to compare continuous variables between two groups, such as age at diagnosis. Pearson's v 2 -test was used to evaluate the association between BRCA1/2 mutation frequency and clinicopathological characteristics of ovarian cancer patients. Each reported p values was two sided, and p < 0.05 was used to infer the statistical significance. All analyses were performed using the SPSS Statistics software v16.0, unless stated otherwise.
Results
BRCA1/2 mutational prevalence
Among 916 consecutively collected blood samples from EOC patients, germline variants in BRCA1 or BRCA2 genes were detected in 194 cases (21.8%) with the exclusion of common polymorphisms (Classes 1 and 2) ( Table 1) . Variants in BRCA1 gene were predominant, representing a total number of 140 (15.3%) patients, whereas variants in BRCA2 were found in 57 (6.2%) patients. Three patients (0.3%) carried variants in both BRCA1 and BRCA2 (see Supporting Information Table S2 for detailed mutation description). Despite potential interests of variants with unknown biological significance, for this study, we only took pathogenic mutations (class 5) into consideration. In total, 153 mutations were classified as pathogenic (16.7%), characterized by frameshifts, nucleotide substitutions leading to stop-codon or affecting canonical splicing sites, or missense mutations that were defined as pathogenic by existing mutation databases (Table 1) . One hundred and twenty out of 153 pathogenic mutations occurred in BRCA1 gene (13.1%) and 36 (3.9%) occurred in BRCA2 gene. Three patients carried variants in both BRCA1 and BRCA2 (0.3%) (Supporting Information  Table S2 ). Most patients were from southeastern China, and the frequencies of pathogenic mutation ranged from 13% to 20% in different provinces (Fig. 1) .
Although the majority of the pathogenic mutations were previously reported, 32 novel mutations were identified in our study, which were not described in the literature [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] nor recorded in public databases, such as BIC, ClinVar or LOVD. Two novel pathogenic mutations in BRCA1: c.283_286delCTTG and c.4573C > T, were both identified in two unrelated EOC patients (Table 2) . Moreover, we found three additional recurrent pathogenic mutations in BRCA1. The mutations c.981_982delAT and c.3770_3771delAG were both found in six unrelated patients and the mutation c.5470_5477del8 was found in ten unrelated patients (Supporting Information Table S3 ). All the patients were unrelated, and we did not find any common haplotype among carriers by using genotype analysis of informative intragenic SNPs (data not shown).
It has been reported that germline BRCA1 and BRCA2 mutations in ovarian cancer patients tended to be concentrated in certain regions denoted as ovarian cancer cluster region (OCCR). 32 In our series, although mutations in the BRCA1 gene spread over the whole coding region, relatively more mutations occurred within exon 11 as shown in Figure 2 . Indeed, out of the 120 BRCA1 mutations found in this cohort, 50 (41.7%) were located in the reported BRCA1 OCCR (c.1380-c.4062). 32 For BRCA2, 16 out of 36 (44.4%) were located in the reported OCCR1 (c.3249-c.5681) 32 and 4 out of 36 (11.1%) were located in OCCR2 (c.6645-c.7471). 32 
Clinicopathological characteristics
The age at EOC onset of 916 patients ranged from 20 to 81 years with 87.6% of cases aging between 41 and 70 at diagnosis. As summarized in Table 1 , the highest pathogenic mutational incidence was found in age groups of 41-50 and 51-60 years (6.2% and 5.7%, respectively) followed by the age group of 61-70 years (3.8%). Only five (0.5%) patients carrying pathogenic mutations were younger than 40 years at diagnosis and four (0.4%) cases in the group of over 70 years. There was no difference of mean ages at diagnosis between pathogenic mutation carriers and overall mutation carriers or noncarriers (53.7 vs. 54.2 or 54.3 years; Student's t test, p 5 0.518). However, patients with BRCA1 pathogenic mutations tended to be diagnosed at younger ages than carriers of BRCA2 mutations (mean age at diagnosis: 52.8 vs. 55.7 years; Student's t test, p 5 0.077) (Supporting Information Table S2 ).
Regarding histological type of tumors, as shown in Supporting Information Table S4 , the serous type with grade 3 (high-grade) disease was predominantly represented (613 cases, 66.9%). Out of 726 patients with serous carcinoma (all tumor grades included), pathogenic mutations occurred in 131 cases (18.0%). In comparison, seven pathogenic mutations were found in 21 high-grade endometrioid tumors (33.3%), and one in three high-grade transitional cell tumors (33.3%). We only found one mutation in patients with clear cell carcinoma (n 5 51, 2.0%). No pathogenic mutation was found in mucinous (n 5 38) or other mixed types (n 5 4). The mutation frequency was 26.8% for adenocarcinoma (n 5 41) ( Table 1) . As for tumor grade, 17.9%, 13.5% and 0% mutations were occurred in tumors with grade 3 (high), 2 (moderate) and 1 (low), respectively.
Personal and family cancer history
Germline pathogenic mutations are associated with HBOC syndrome. In this study, available information about family and personal history of HBOC-related tumors in patients was detailed in Supporting Information Table S5 . Five mutations were clearly associated with HBOC syndrome since the same mutations were found in affected family members (Y0101, EOC0276, Y0201, Y0701 and 224). Thus, a familial segregation of mutation in these families could be ascertained (Supporting Information Table S5 ). The HBOC syndrome could also be diagnosed in other 12 patients because they developed uni-or bilateral breast cancers (Table 1) . For 22 additional patients, HBOC related cancers were detected in their first or second degree relatives. Overall, 39 out of 153 (25.5%) patients with BRCA1/2 pathogenic mutations (Class 5) were associated with familial aggregations of breast or/and ovarian cancer suggestive of HBOC syndrome.
Discussion
This is, to our knowledge, the first large-scale study for BRCA1/2 mutation screening in Chinese ovarian cancer patients. In this unselected and consecutive series of EOC patients, we found an overall frequency of 16.7% cases harboring BRCA1/2 pathogenic mutations. Mutations were more prevalent in the BRCA1 gene (13.1%) comparing to those in BRCA2 (3.9%). Two novel BRCA1 mutations, c.283_286delCTTG and c.4573C > T, were both identified in two unrelated EOC patients. In this study, gross genomic deletion/duplications were not assessed by using the conventional Multiplex ligationdependent probe amplification (MLPA) strategy. As a consequence, such genomic alterations may have been missed. Of note, the frequency of large rearrangements in BRCA1 and BRCA2 is reported to be <10% of all BRCA1/2 mutations in Asian population. 33 A substantial proportion of mutations (41.7% for BRCA1 and 55.5% for BRCA2) were localized in OCCRs. These findings suggested that, consistent with BRCA1/2 mutation carriers in Western countries, 32 mutations in these OCCR regions seemed to be also associated with an increased risk of ovarian cancer in Chinese patients. However, the two novel recurrent mutations were not localized in OCCRs of the BRCA1 gene. In addition, five OCCR-related BRCA1 mutation carriers were diagnosed with breast cancer prior to the diagnosis of ovarian cancer, which indicated that the OCCR was not exclusively linked to ovarian cancer in Chinese women. Nevertheless, no such discordance was found in OCCR-related BRCA2 mutation carriers.
The frequency of pathogenic mutations in BRCA1/2 genes was similar to that previously reported in populations from Western countries and Caucasian population in Australia. 11 No significant difference was found in mutation distribution among different groups of histological tumor types. As high as 74.5% and 7.8% of the pathogenic mutations were found in high-(613 cases) and moderate-(76 cases) grade serous ovarian cancer, respectively, followed by 5.9% of mutations in endometrioid type (49 cases) (Supporting Information  Table S4 ), which is in agreement with previous studies. 34, 35 Overall, the BRCA1/2 associated tumors were more likely to exhibit a high tumor grade, serous type of cancer and personal or familial history of the HBOC syndrome.
Germline BRCA1/2 mutations lead to an increased risk of early onset of the HBOC-related tumors, i.e., breast, ovarian, pancreatic cancers in women and cancers of breast and prostate in men. In our series, the highest mutation frequency was found in age groups of 41-60 years. No significant difference was observed regarding the age of ovarian cancer onset between carriers and noncarriers of mutation (53.7 vs. 54.3 years). When taking the age at onset of the first tumor into account (i.e., if breast cancer occurred earlier than ovarian cancer) for patients with multiple primary tumors, the mean age was 52.9 years for mutation carriers. Carriers of BRCA1 mutations were younger than those of BRCA2 mutations (mean age: 52.8 vs. 55.7 years) at diagnosis, consistently with the previous report. 12 Personal cancer history and familial aggregations of HBOC-related tumors were observed only in less than a third of patients carrying a pathogenic mutation. This situation was apparently not uncommon as discussed in a recent review. 20 In addition, generally small-sized nuclear families in China which lead to limited phenotype expression made the aggregation evaluation even more difficult.
Previous studies in Chinese populations reported several recurrent mutations either from ovarian cancer patients or patients with HBOC syndrome, 16, 17 such as c.2371_2372delTG and c.3780_3781delAG in BRCA1, c.3337C > T, c.3109C > T and c.5682C > G in BRCA2, as well as putative founder mutations including c.1081delG, c.5154G > A and c.5468-1del8 in BRCA1. In comparison, we did not find any presumed founder mutations in ovarian cancer patients. One possible reason might be the heterogeneity in Chinese populations; for example, these founder mutations were likely geographically restricted in South China (Hong Kong) population. Therefore, it is necessary to conduct genetic analysis by stratifying populations originated from different regions.
Three recurrent BRCA1 mutations were identified in this study, including c.981_982delAT, c.5470_5477del8 and c.3770_3771delAG. Interestingly, the c.5470_5477del8 mutation in BRCA1 has not or rarely been recorded in consultable databases. This truncating mutation is located in the BRCT domain of the protein. The fact that it was recurrently found in patients with HBOC or ovarian cancer but not in general population (not recorded in the dbSNP and the 1,000 Genome Project databases) strongly supported its pathogenicity. All previously reported cases affected by this mutation were Asian patients from China 20 and South Korea. 36, 37 This mutation seemed to be substantially enriched in Chinese populations and was reported mostly from HBOC breast cancer patients. Based on data from cohorts of >200 patients, the incidence was reported to be 0.1% (1/505), 0.3% (2/625) and 0.4% (1/219). [38] [39] [40] [41] Compiled data by Kim et al. 20 identified 20 mutation carriers out of 3,844 breast cancer patients from Chinese HBOC families (0.5%). The hypothesis of being a founder mutation in Chinese populations was not supported by the haplotype assessment. 38 On the contrary, in our series of ovarian cancer patients, the incidence of c.5470_5477del8 was particularly high. In fact, it was found in 1.1% of all 916 cases regardless of mutation status and familial history of HBOC, in 6.5% of all pathogenic mutations and in 8.3% of BRCA1 mutations. In accordance with previous studies, we failed to observe a shared haplotype by evaluating intergenome SNPs among ten carriers. Taken together, the c.5470_5477del8 mutation appeared, with little doubt, to be a high-frequency mutation in Chinese (or Asian) population. The mechanism underlying this populationrelated hot-spot variant other than a founder mutation remained to be elucidated. On the other hand, our results raised the question whether BRCA1 c.5470_5477del8 was linked to an increased risk of ovarian cancer. Indeed, the mutation incidence in this series of ovarian cancer patients was twice higher than that found in breast cancer probands from HBOC families (p 5 0.049). In our cohort, eight carriers were diagnosed with ovarian cancer without other malignancies, and two out of ten patients also had personal and familial history of breast cancer. Unfortunately, the lack of complete clinicopathological information in previous studies made a systemic assessment difficult. Based on our observations, we speculated that there was an association of the c.5470_5477del8 germline mutation with an increased risk of ovarian cancer. Further investigations are required to confirm this hypothesis.
In conclusion, we reported here a large-scale BRCA1/2 mutation screening in Chinese EOC patients. The mutational incidence was comparable to that in Western populations. Thirty-two mutations were found to be novel. Moreover, we found the recurrent c.5470_5477del8 mutation as a Chinese ethnic-related hot-spot alteration in BRCA1 with presumably an increased risk for ovarian cancer. These findings allow for a more complete assessment of BRCA1/2 mutation prevalence worldwide and will be useful in clinical management of affected families. Indeed, mutation carriers from affected families will be able to benefit from genetic counseling and appropriate clinical surveillance. However, no clear distinctive clinical features were observed in the identified mutation carriers. Personal and familial history of HBOC might be underestimated in a proportion of EOC patients because of the recall bias from the retrospective study. The lack of familial information is accentuated in China due to the generally small family sizes. Therefore, it seems necessary to recommend the BRCA1/2 genetic testing to all Chinese women diagnosed with EOC to identify HBOC families for which proper genetic counseling will be provided. Adapted clinical surveillance will be suggested to at-risk relatives. On the other hand, affected mutation carriers will be able to benefit from PARP-targeted treatment.
